Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-GEOD-60424

ABSTRACT: Next generation sequencing of human immune cell subsets across diseases

OTHER RELATED OMICS DATASETS IN: PRJNA258216

DISEASE(S): Type 1 Diabetes,Multiple Sclerosis,Als,Sepsis,Normal

PROVIDER: E-GEOD-60424 | ExpressionAtlas | 2019-05-14

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-GEOD-60424-analysis-methods.tsv	Tabular
	E-GEOD-60424-analytics.tsv	Tabular
	E-GEOD-60424-analytics.tsv.undecorated	Tabular
	E-GEOD-60424-analytics.tsv.undecorated.unrounded	Tabular
	E-GEOD-60424-analytics.tsv.unrounded	Tabular

Items per page:

1 - 5 of 515

Similar Datasets

Homo sapiens

Project description:Next generation sequencing of human immune cell subsets across diseases

| PRJNA258216 | ENA

Next generation sequencing of human immune cell subsets across diseases

Project description:This study compared whole transcriptome signatures of 6 immune cell subsets and whole blood from patients with an array of immune-associated diseases. Fresh blood samples were collected from healthy subjects and subjects diagnosed type 1 diabetes, amyotrophic lateral sclerosis, and sepsis, as well as multiple sclerosis patients before and 24 hours after the first treatment with IFN-beta. At the time of blood draw, an aliquot of whole blood was collected into a Tempus tube (Invitrogen), while the remainder of the primary fresh blood sample was processed to highly pure populations of neutrophils, monocytes, B cells, CD4 T cells, CD8 T cells, and natural killer cells. RNA was extracted from each of these cell subsets, as well as the whole blood samples, and processed into RNA sequencing (RNAseq) libraries (Illumina TruSeq). Sequencing libraries were analyzed on an Illumina HiScan, with a target read depth of ~20M reads. Reads were demultiplexed, mapped to human gene models (ENSEMBL), and tabulated using HTSeq. Read count data were normalized by the TMM procedure (edgeR package). We performed whole genome RNAseq profiling of immune cell subsets and whole blood from subjects with an array of immune-associated diseases.

2015-01-06 | E-GEOD-60424 | biostudies-arrayexpress

Molecular Profiling to Improve Outcome of Patients in Cancer. A Pilot Study

Project description:Next Generation Sequencing in cancer: a feasibility study in France to assess sample circuit and to perform analyzes within a limited time.

| 2274538 | ecrin-mdr-crc

Homo sapiens

Project description:Next Generation Sequencing Approaches to Childhood Neurological Diseases

| PRJNA314926 | ENA

Project description:Next generation sequencing for hereditary chronic liver diseases

| PRJEB62846 | ENA

Next Generation Sequencing Approaches to Childhood Neurological Diseases

Project description:Next Generation Sequencing Approaches to Childhood Neurological Diseases

| PRJNA314925 | ENA

Unraveling cell type–specific and reprogrammable human replication origin signatures associated with G-quadruplex consensus motifs

Project description:Short nascent strands purification coupled to next-generation sequencing allowed us to identify replication origins on human genome in an extensive way, by mapping replication origins in 4 different cell types, IMR-90 fibroblasts, hESC H9 cells, iPSC Th Cl-4 cells and HeLa cells. We demonstrated the existence of a cell type-specific reprogrammable signature of the cell identity revealed by specific efficiencies of conserved origin positions and not by the selection of cell-type specific subsets of origins. 4 different cell types were analyzed. For each cell types, 2 different biological replicates of short nascent strands at replication origins were purified. Each SNS sample was sequencing at least one time.

2012-07-01 | E-GEOD-37757 | biostudies-arrayexpress

Immunotherapy for Third Line Metastatic Colorectal Cancer

Project description:This is a Phase IIB multi-site, open label study of a next generation immunotherapy for third-line MSI-S metastatic colorectal cancer using an "off-the-shelf", non-genetically manipulated living immune cell product (AlloStim) derived from the blood of healthy donors.

| 2343551 | ecrin-mdr-crc

Operational tolerance after hematopoietic stem cell transplantation is characterized by distinct transcriptional, phenotypic, and metabolic signatures (Cohort 2).

Project description:The mechanisms underlying operational tolerance after hematopoietic stem cell transplantation in humans are poorly understood. We studied two independent cohorts of patients who underwent allogeneic hematopoietic stem cell transplantation from human leukocyte antigen-identical siblings. Primary tolerance was associated with long-lasting reshaping of the recipients' immune system compared to their healthy donors with an increased proportion of regulatory T cell subsets and decreased T cell activation, proliferation, and migration. Transcriptomics profiles also identified a role for nicotinamide adenine dinucleotide biosynthesis in the regulation of immune cell functions. We then compared individuals with operational tolerance and nontolerant recipients at the phenotypic, transcriptomic, and metabolomic level. We observed alterations centered on CD38<sup>+</sup>-activated T and B cells in nontolerant patients. In tolerant patients, cell subsets with regulatory functions were prominent. RNA sequencing analyses highlighted modifications in the tolerant patients' transcriptomic profiles, particularly with overexpression of the ectoenzyme <i>NT5E</i> (encoding CD73), which could counterbalance CD38 enzymatic functions by producing adenosine. Further, metabolomic analyses suggested a central role of androgens in establishing operational tolerance. These data were confirmed using an integrative approach to evaluating the immune landscape associated with operational tolerance. Thus, balance between a CD38-activated immune state and CD73-related production of adenosine may be a key regulator of operational tolerance.

2021-12-22 | MTBLS221 | MetaboLights

Operational tolerance after hematopoietic stem cell transplantation is characterized by distinct transcriptional, phenotypic, and metabolic signatures (Cohort 1).

2021-12-22 | MTBLS220 | MetaboLights